1.13  0.01 (0.87%)		10-24 14:55
Open: 1.14 High: 1.15 Volume: 153,100		Pre. Close: 1.13 Low: 1.0851 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	1.34	1-year :	1.56
Resists	First :	1.14	Second :	1.34
Pivot price	1.01
Supports	First :	0.97	Second :	0.86
MAs	MA(5) :	1.05	MA(20) :	1.01
	MA(100) :	0.87	MA(250) :	0.9
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	84.6	D(3) :	68.7
RSI	RSI(14): 69
52-week	High :	2.22	Low :	0.53

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BFRI ] has closed Bollinger Bands are 10.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.13 - 1.13	1.13 - 1.14
Low:	0.99 - 0.99	0.99 - 1
Close:	1.12 - 1.13	1.13 - 1.14

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Thu, 23 Oct 2025
Biofrontera Inc Closes Restructuring and Asset Purchase Agreement - TradingView

Thu, 23 Oct 2025
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG - GlobeNewswire

Thu, 23 Oct 2025
Biofrontera (NASDAQ: BFRI) acquires U.S. Ameluz and RhodoLED rights, $11M funding - Stock Titan

Sat, 04 Oct 2025
Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Its Share Price - simplywall.st

Fri, 03 Oct 2025
Benchmark reiterates Buy rating on Biofrontera stock amid tariff concerns - Investing.com

Fri, 26 Sep 2025
Dermatology Leader Biofrontera Announces Key Investor Conference Presentation at Lytham Fall 2025 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	11 (M)
Shares Float	8 (M)
Held by Insiders	14.8 (%)
Held by Institutions	21.9 (%)
Shares Short	118 (K)
Shares Short P.Month	187 (K)

EPS	-1.83
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.47
Profit Margin	-42.4 %
Operating Margin	-56.3 %
Return on Assets (ttm)	-48.9 %
Return on Equity (ttm)	-531.6 %
Qtrly Rev. Growth	15.1 %
Gross Profit (p.s.)	2.16
Sales Per Share	3.67
EBITDA (p.s.)	-1.51
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	4 (M)

PE Ratio	-0.63
PEG Ratio	0
Price to Book value	-2.48
Price to Sales	0.31
Price to Cash Flow	-1.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.